1. South Korea Stocks

  2. •

    Electronic technology

  3. •

    Electronic components
CHA Biotech Co., Ltd.

CHA Biotech Co., Ltd.

KKRX:085660
7,160.00
KRW
-210.00
(-2.85%)
-1,473.49EPS
1.61TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7,632.05
5,786.15
7,412.68
8,451.73
7,823.02
8,803.01
9,407.64
11,675.24
12,307.78
13,857.49
15,667.36
17,235.48
18,895.2
16,826.6
Basic EPS, GAAP
502.1
-72.6
-281.56
216.02
-871.45
439.42
816.06
-327.72
-236.33
-780.06
-138.47
-78.56
-1,637
-955.28
Free Cash Flow per Basic Share
471.25
-972.93
574.25
-302.5
-461.44
-36.31
-1,555.55
-1,446.38
-1,577.23
-2,452.96
-1,032.45
-2,441.74
-3,346.06
-3,789.51
Dividend per Share
0.37
- -
13.23
37.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7,273.54
5,586.62
5,420.43
4,955.19
4,246.03
5,752.16
6,634.74
6,238.05
7,483.15
4,786.2
4,612.04
4,671.92
3,276.43
5,537.96
Tangible Book Value per Share
6,096.68
4,496.36
4,479.72
4,493.2
3,818.25
4,830.13
5,694.13
5,310.73
6,613.66
3,416.04
3,183.96
1,289.71
837.08
2,950.32
Basic Weighted Avg Shares
51
60
53
53
53
56
57
57
59
61
61
61
67
77
Sales/Revenue/Turnover
386,835
345,345
393,782
449,261
417,460
488,600
534,612
664,717
727,476
844,583
953,951
1,045,049
1,268,254
1,293,819
Operating Margin (%)
6.9
3.38
2.97
7.28
-1.6
3.89
1.09
-0.31
1.06
-5.57
-0.99
-5.71
-3.82
-5.13
Depreciation Expense
23,822
17,367
15,945
15,288
13,120
14,902
22,414
25,442
27,862
32,520
37,799
45,009
56,293
57,133
Net Income, GAAP
25,449
-4,333
-14,957
11,483
-46,503
24,389
46,375
-18,658
-13,968
-47,543
-8,431
-4,764
-109,876
-73,453
Effective Tax Rate (%)
43.58
65.73
- -
40.37
- -
0.51
22.2
- -
- -
- -
274.41
- -
- -
- -
Profit Margin (%)
6.58
-1.25
-3.8
2.56
-11.14
4.99
8.67
-2.81
-1.92
-5.63
-0.88
-0.46
-8.66
-5.68
Working Capital
325,617
258,220
254,581
196,883
242,456
235,620
293,242
282,298
155,378
42,519
-116,700
-286,823
-435,048
-140,751
LT Debt
5,188
14,638
5,792
32,439
65,554
87,753
173,223
244,136
231,201
334,801
132,994
279,373
224,522
368,671
Total Equity
512,345
437,454
446,563
349,549
408,456
550,247
666,298
636,876
793,112
651,936
656,334
709,231
809,249
1,017,386
Return on Invested Capital (%)
3.48
0.83
- -
4.44
- -
3.13
0.58
- -
- -
- -
1.56
- -
- -
- -
Return on Capital (%)
5.85
-2.15
- -
0.86
- -
3.73
6.32
- -
- -
- -
-5.75
- -
- -
- -
Return on Common Equity (%)
7.36
-1.27
-5.09
4.13
-18.74
8.75
13.17
-5.1
-3.44
-12.72
-2.94
-1.68
-37.27
-18.24

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
615,749
680,911
583,645
LT Borrowings
147,056
159,913
304,288
LT Finance Leases
61,238
64,608
64,383
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
93
93
Market Capitalization
846,802
1,363,866
1,613,025

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
796,680
888,137
1,032,582
Cash, Cash Equivalents & STI
337,529
339,225
435,813
Accounts Receivable, Net
120,325
134,964
152,318
Inventories
48,484
59,603
59,517
Total Current Liabilities
1,192,372
1,323,185
1,173,333
Payables & Accruals
- -
- -
- -
ST Debt
615,749
680,911
583,645
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.61%
5.91%
14.1%
Free Cash Flow
429.13%
40.57%
51.7%
Net Income, GAAP
141.17%
459.21%
2,206.57%
Sales/Revenue/Turnover
12.72%
13.88%
21.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
232,404
264,645
272,016
275,984
1,045,049
2025
304,140
298,895
318,675
346,543
1,268,254
2026
329,706
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-239.09
45.23
482.81
-363.73
-78.56
2025
-343.41
-975.6
-147.76
-238.52
-1,637
2026
175.66
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Won-Tae Cha
Full Time Employees
354
Sector
Electronic technology
Industry
Electronic components
Address
442 Dosan-daero Seoul SL South Korea
IPO Date
Dec 27, 2005
Website
chabio.com
Similar Companies
Corning Incorporated (NYSE:GLW)
Taiyo Yuden Co., Ltd. (TSE:6976)
Celestica, Inc. (NYSE:CLS)
Amphenol Corporation (NYSE:APH)
IBIDEN CO., LTD. (TSE:4062)
Vicor Corporation (NASDAQ:VICR)
Business
Chabiotech Co., Ltd. Chabiotech Co., Ltd. (085660.KQ) engages primarily in the development and commercialization of cell and gene therapies, alongside cord blood banking, stem cell storage, regenerative medicine, and immune cell treatments in South Korea and internationally. The company offers core products and services including umbilical cord blood consignment storage for incurable diseases; regenerative medicines such as CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson’s disease, and hESC-RPE for macular degeneration; immune cell therapies like CBT101 for recurrent glioblastoma and solid cancers, CBT111, and CAR-NK cells; medical wellness programs encompassing fitness, spa, and supplements; in vitro fertilization (IVF) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; and customized research, development, production, clinical trials, and commercialization support, with operations spanning the United States, South Korea, Singapore, Japan, Australia, Indonesia, and Vietnam. Founded in 2002 and headquartered in Seoul, South Korea, Chabiotech Co., Ltd. operates through bio and legacy optical segments, including lens modules for mobile devices, while leveraging subsidiaries like CHA Vaccine Research Institute and Organoid Sciences for advanced R&D in stem cells, vaccines, and next-generation therapies. Recent developments include the acquisition of Kakao Healthcare in November 2025 to enter AI-based digital health; expansion of Matika Bio Labs with CDMO contracts for antiviral therapies and AAV vectors with U.S. partners like Kallidi Biotherapeutics and Surgium Bio; plans for an IPO of CHA Healthcare following its merger with CHA Cares; establishment of Total Cell Clinic Tokyo as a regenerative medicine hub; strategic focus on cost reduction in gene and cell therapies to one-tenth of current levels; and pipeline advancements such as CHAB-101 for immuno-oncology combinations and CHAB-102/103 for autoimmune diseases under Korea's Advanced Regenerative Medicine Act effective February 2025.